Registration Now Open for PHA’s Expo22 this
Fall—October 25-26
|
|
Register early for the PHA Expo 22, set for October 25-26, to secure your on-site seat!
We’re pleased to be hosting this distinctive in-person event, “PHA22 Expo 2022-Decision Maker’s Connect” in Washington, DC this fall at the Top of the Hill Conference Center, that is a must attend! As your only Population Health Improvement professional and trade Association, the event will focus on marketplace needs, spoken from the solution buyers’ themselves. The intimate environment will allow you to meet directly with PHA Board members, Hill staffers, and senior leadership colleagues that are your existing and future business partners.
The interactive sessions and networking opportunities will include:
- CMMI Priorities and Strategies
-
Medicaid - Population Health Needs Amidst Growing Challenges
-
Senior Health - Ramping Up Aging in Place Support
- Employer Value-based Approaches to Benefit Design and Health Promotion
- Advanced Analytics Across Market Segments
- Public Private Partnerships to Achieve Community Health
Across these market-focused sessions, topical issues such as chronic condition prevention and management, addressing the growing behavioral health crisis, and supports for social determinants of health and health equity, will also be addressed by multi-disciplinary industry leading experts.
|
|
Take a Look at the Featured Speakers |
|
TRICIA BARRETT, MHSA
Executive Director of Quality and Population Health Strategy, Bayer US Pharmaceuticals
|
|
RAY FABIUS
Co-Founder and
Chief Medical Officer, HeathNEXT
|
|
RUSHIKA FERNANDOPULLE
Chief Innovation Officer,
One Medical, and former Co-Founder & CEO,
Iora Health
|
|
NEIL GOLDFARB
President & CEO, Greater Philadelphia Business Coalition on Health
|
|
CATHRYN GUNTHER
Global Head Associate Health and Wellbeing,
Mars
|
|
BILL LUCIA
Principal, Bill Lucia Associates, LLC, and
former CEO of HMS
|
|
ROSE MALJANIAN
Chairman & CEO HealthCAWS and PHA Chairman of the Board Emeritus
|
|
NICO PRONK
President,
HealthPartners Institute
|
|
MICHAEL ROIZEN, MD
Chief Wellness Officer Emeritus, Cleveland Clinic
|
|
JAMO RUBIN, MD
Co-Founder and
Executive Chair,
RighSite Health
|
|
GLEN TULLMAN (invited)
Chief Executive Officer, Transcarent
|
|
SANDEEP WADHWA, MD
3M Global Chief Medical Officer Health Information Systems Division
|
|
PHA BH Workgroup Releases Issue Brief on Integrated Care |
|
Integrating Behavioral Health, Medical and SDOH care and supports is vital to success in Population Health Management. In recognition of Mental Health Awareness month, the PHA Behavioral Health Workgroup recently released an Issue Brief, entitled “Achieving Success in Population Health Management with Integrated Care.” The effort was led by workgroup Chair Matt Miclette, Senior Director of Clinical Operations at NeuroFlow. Click on the button below, provide your contact info to download a copy.
|
|
Announcing Launch of New Medicaid Workgroup |
|
PHA is launching a new Medicaid workgroup that will unify all stakeholders to deliver innovative solutions for the nations’ most vulnerable individuals. The group will be led by PHA Board Member Bill Lucia, Principal of Bill Lucia Associates, LLC and former Chairman and CEO of HMS, and Leesa Allen, Director of Sellers Dorsey, and former Executive Deputy Secretary for the Department of Human Services (DHS) in Pennsylvania, as well as the Commonwealth’s Medicaid Director.
The group will consist of PHA member companies which desire to impact policy, quality, and cost for companies and improve access, health outcomes, and mitigate social and health equity barriers to achieve optimal outcomes for Medicaid members.
“Given the leadership established for this effort, and the commitment Sellers Dorsey has made to the Medicaid market segment, I have no doubt the contributions and impact will be tremendous.” stated Rose Maljanian Chairman & CEO HealthCAWS, Inc. and Chairman Emeritus PHA Board of Directors. Bill Lucia stated: "I am proud to co-chair this workgroup with Leesa Allen to address the real-world issues facing the Medicaid population and those that serve Medicaid."
If you are employed by a PHA member company and would like to participate, please email us at staff@populationhealthalliance.org. And if you would like to join the Population Health Alliance, click here to become a member or learn more. We look forward to working with you!
|
|
Take a look at some of the latest happenings from our PHA Members: |
|
New Blue Cross Blue Shield Association Report Shows Glaring Racial Disparities in Diagnosis and Treatment of Major Depression
The Blue Cross Blue Shield Association (BCBSA) recently released new data that found major depression goes undiagnosed and untreated at disproportionately greater rates in majority Black and Hispanic communities. The study investigates the prevalence of diagnosis and treatment of major depressive disorder, or major depression, to quantify the extent of racial and ethnic inequities in mental health and help inform potential solutions. Diagnosis rates were nearly 31-39% lower among individuals living in majority Black and Hispanic communities. Read full story.
|
|
Bayer's BlueRock Therapeutics Announces Completion of Enrollment on Phase 1 Trial in Patients with Parkinson's Disease
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced the completion of enrollment of its Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson’s disease. The purpose of the Ph1 clinical trial is to evaluate the safety, tolerability, and preliminary efficacy of BRT-DA01 in patients with Parkinson’s disease. Read full release.
|
|
NACDD Awarded Five-Year Cooperative Agreement to Improve Emotional Health and Well-Being of Students and School Staff
The National Association of Chronic Disease Directors (NACDD) was awarded a cooperative agreement from the Centers for Disease Control and Prevention (CDC)’s Healthy Schools Branch to improve the health and well-being of children, adolescents, and school staff in communities that are underserved, economically marginalized, and disproportionately affected by chronic diseases and chronic disease risk factors. This project will partner and collaborate with other programs in the Center for Advancing Healthy Communities. Read full article.
|
|
American College of Lifestyle Medicine Publishes Consensus Statement with Multiple Society Support on Use of Diet as a Primary Intervention to Achieve Diabetes Remission
The American College of Lifestyle Medicine has released an expert consensus statement to assist clinicians in achieving remission of type 2 diabetes in adults using diet as a primary intervention. The expert consensus statement is endorsed by the American Association of Clinical Endocrinology (AACE), supported by the Academy of Nutrition and Dietetics (AND) and co-sponsored by the Endocrine Society. This unique publication in the American Journal of Lifestyle Medicine is the first to focus on diet as primary means of achieving lasting remission of diabetes—without medications or procedures—in contrast with the usual role of diet as an adjunctive therapy. Knowing that diet alone can achieve remission is an empowering message for many adults with type 2 diabetes, especially when supported by consensus among internists, cardiologists, family physicians, endocrinologists, nutritionists, dieticians and lifestyle medicine specialists. Click to read statement.
|
|
NCQA Releases White Paper on the Impact of Telehealth on Health Equity
|
|
Jefferson Investigates: A New Disease, COVID Immunity and Triple Combo Therapy for Glioblastoma
Read new article from the Jefferson addressing a novel fibrotic disease with surprising nerve symptoms, an explanation for COVID immunity in the immunocompromised and a new approach for brain cancer. Read full article.
|
|
Geisinger Named to Forbes List of Best Employers for New Graduates
Geisinger has been named to the 2022 Forbes list of Best Employers for New Graduates. The rankings were selected based on Statista's innovative methodology, guaranteeing unbiased results and providing reliable insights. More than 20,000 U.S. young professionals who work for companies that employ at least 1,000 people participated in the independent survey, which focused on work-related issues and their experiences in the workplace. Read full announcement.
|
|
Mutual of Omaha Introduces New Hospital Indemnity Product
Mutual of Omaha has launched a new hospital indemnity product that enhances its employer-provided benefits packages. Hospital indemnity insurance can help fill the gaps and cover unexpected costs that an employee’s health insurance may not—so they are prepared to handle the hospital expenses and focus on recovery. Mutual of Omaha’s hospital indemnity insurance offers complete, competitive and flexible plan designs that can be packaged with other products on one bill. Benefits and plan options are fully customizable and include HSA and non-HSA compatible features. Read full release.
|
|
Welldoc Earns 2022 Great Place to Work Certification™
Welldoc®, a digital health leader revolutionizing chronic care, today announced that it was Certified™ by Great Place to Work®. The prestigious award is based entirely on feedback from current employees regarding their experience working at Welldoc. This year, 95 percent of employees said Welldoc is a great place to work—36 points higher than the average U.S. company. Great Place to Work® is the global authority on workplace culture, employee experience and the leadership behaviors proven to deliver market-leading revenue, employee retention and increased innovation. Read full release.
|
|
Wholesome Wave Applauds the USDA on the Expansion of Produce Prescriptions in the Gus Schumacher Nutrition Incentive Program
Wholesome Wave, the national leading nonprofit working to eliminate disparities in diet-related disease across the United States recently extended congratulations and support to Secretary of Agriculture Tom Vilsack and the entire team at USDA on their announcement of a robust framework for shoring up the food supply chain and transforming the food system to be fairer, more competitive, and more resilient. Among the important policies announced were a major expansion of produce prescriptions in the Gus Schumacher Nutrition Incentive Program (GusNIP), enacted in the 2018 farm bill that honors our co-founder. Read full release.
|
|
Article released on Mediterranean Diet vs. Precision Nutrition: Which is Better for Blood Sugar Control?
DayTwo’s scientific founders, Profs. Eran Segal and Eran Elinav of the Weizmann Institute in Israel, recently published a study1 evaluating two options for blood sugar control. In a randomized clinical trial for early-stage type 2 diabetes, they demonstrated the superiority of DayTwo’s precision nutrition algorithm in a head-to-head comparison with the commonly recommended (and ADA-backed) Mediterranean diet. After six months of dietary intervention, they showed significant clinical benefits using the DayTwo algorithm, including a reduction in A1C levels to the extent of diabetes remission. Read more.
|
|
CareOregon Invests More Than $210,000 in Metro Area Non-Profits to Support Health Equity
CareOregon recently announced that it has awarded $210,000 in community giving grants to nine local nonprofit organizations that provide social support and improve access to medical care for seniors, communities of color and other underrepresented communities across the Portland metropolitan region. These grants are part of CareOregon’s commitment to reduce health disparities in communities by supporting programs that work to remove barriers to health and improve healthy equity. Read full release.
|
|
Nova Scripts Central Awarded NAFC 2022 Standards Gold
|
|
Adjuvant Treatment with Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with Resected Stage IIB or IIC Melanoma in Phase 3 KEYNOTE-716 Trial
Merck recently announced distant metastasis-free survival (DMFS) results from the Phase 3 KEYNOTE-716 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, versus placebo as adjuvant therapy for patients with resected stage IIB or IIC melanoma. With a median follow-up of 27.4 months, KEYTRUDA demonstrated a statistically significant and clinically meaningful improvement in DMFS versus placebo (HR=0.64 [95% CI, 0.47-0.88]; p=0.0029). Median DMFS was not reached in either arm. These late-breaking data are being presented for the first time today at 10:45 a.m. ET during an oral abstract session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (abstract #LBA9500). Read full release.
|
|
Eyenuk Wins Juniper Research's Digital Health Innovation Award for Best Digital Diagnostics Solution
Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™ and AI Predictive Biomarkers™, just announced its EyeArt® AI System won Juniper Research's Future Digital Health award for the "Best Digital Diagnostics Solution". Juniper Research's Future Digital Health Innovation Awards are presented to companies that deliver imaginative, innovative products or services that have the potential to disrupt their ecosystems and provide significant benefits to their target audience. Entries are initially assessed by a Juniper Research analyst panel, which then draws up a shortlist of potential winners based on a number of criteria, including product innovation, features and benefits, and future business prospects. Read full release.
|
|
UK National Screening Committee Report Singles Out Eyenuk's EyeArt as the Only Diabetic Eye Screening AI Technology Ready for Live Clinical Implementation in the National Health Service
Eyenuk, Inc., also recently announced its EyeArt® system has been confirmed to have “sufficient high quality evidence” as “safe and cost-effective,” and is the only diabetic eye screening AI technology ready for live clinical implementation in the United Kingdom, according to the report. Read full article.
|
|
Franciscan Health and Lurie Children's Partner to Provide Top Neonatal Care in Northwest Indiana
Franciscan Health Crown Point and Ann & Robert H. Lurie Children's Hospital of Chicago announce a new partnership that will bring one of the nation's top neonatology programs to Northwest Indiana. Beginning September 2022, Lurie Children's neonatologists will staff the 20-bed Level 3 neonatal intensive care unit (NICU) at Franciscan Health Crown Point, caring for the most vulnerable babies and their families close to home. Read more here.
|
|
Are you a PHA Member with news to share?
We'd love to include it in this section!
any news or press releases. We will include as many as we can each month.
|
|
PHA and our upcoming EXPO22 are supported by: |
|
Like to see your logo here? To explore PHA's sponsorship opportunities for our upcoming October Expo or Corporate Partnerships offerings, click on above button.
Or not yet a PHA member and interested in learning more?
Download a membership guide, or click the 'JOIN' button below.
|
|
|
|
|
|
|
